Sanofi (SNY) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Sanofi (SNY) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
14.49% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
168.07% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-52.40% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
-45.93% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-182.77% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
5.14% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
53.69% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
- |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
8.81% |
| 10 |
Sanofi |
63.47 Mn |
-6.87 Bn |
9.49 Bn |
-83.37% |
| Date | Value |
|---|
| Mar 31, 2026 |
-83.37% |
| Dec 31, 2025 |
-1,655.15% |
| Sep 30, 2025 |
7,513.84% |
| Jun 30, 2025 |
6,223.19% |
| Mar 31, 2025 |
7.31% |
| Dec 31, 2024 |
59.73% |
| Sep 30, 2024 |
-99.01% |
| Jun 30, 2024 |
-98.09% |
| Mar 31, 2024 |
-94.86% |
| Dec 31, 2023 |
-107.07% |
| Sep 30, 2023 |
28.88% |
| Jun 30, 2023 |
40.32% |
| Mar 31, 2023 |
4.90% |
| Dec 31, 2022 |
2,204.94% |
| Sep 30, 2022 |
-21.32% |
| Jun 30, 2022 |
-21.03% |
| Mar 31, 2022 |
2.43% |
| Dec 31, 2021 |
-98.03% |
| Sep 30, 2021 |
91.97% |
| Jun 30, 2021 |
222.75% |
